Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience

Table 4

Survival analysis of those who had received bevacizumab and/or cetuximab prior to treatment with ⁹⁰Y.

	n (%)	Median Survival (months)	95% CI^1
Failed cetuximab	44 (100)		𝑃=.𝟎𝟎𝟏
Yes	16 (36.4)	5.1	2.6–7.5
No	28 (63.6)	18.3	6.5–30.0
Failed bevacizumab	44 (100)		𝑃=.𝟑𝟔
Yes	17 (38.6)	8.2	5.0–11.4
No	27 (61.4)	17.0	6.7–27.3
Failed both bevacizumab and cetuximab	44 (100)		𝑃=.𝟎𝟎𝟏
Yes	9 (20)	5.2	2.9–7.4
No	35 (80)	13.6	4.9–22.2

¹ 95% Confidence interval.